Donepezil for mild cognitive impairment in Parkinson’s disease

Kyoungwon Baik, Seon Myeong Kim, Jin Ho Jung, Yang Hyun Lee, Seok Jong Chung, Han Soo Yoo, Byoung Seok Ye, Phil Hyu Lee, Young H. Sohn, Seung Wan Kang, Suk Yun Kang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson’s Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.

Original languageEnglish
Article number4734
JournalScientific reports
Volume11
Issue number1
DOIs
Publication statusPublished - 2021 Dec

Bibliographical note

Funding Information:
This study was funded by Eisai Korea Inc.

Publisher Copyright:
© 2021, The Author(s).

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Donepezil for mild cognitive impairment in Parkinson’s disease'. Together they form a unique fingerprint.

Cite this